ArangoC, GiraldezM, Merchan-NaranjoJ, BaezaI, Castro-FornielesJ, AldaJ, Martınez-CantareroM, MorenoC, de AndresP, CuerdaC, de la SernaE, CorrellC, FraguasD, ParelladaM: Second-generation antipsychotic use in children and adolescents: A six-month prospective cohort study in drug-naïve patients. JAACAP, 53: 1179–1190, 2014.
2.
CorrellCU: Antipsychotic use in children and adolescents minimizing adverse effects to maximize outcomes. Journal of American Academy of Child and Adolescent Psychiatry, 47: 9–20, 2008.
3.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302: 1765–1773, 2009.
4.
DrielingT, BiedermannNC, SchärerLO, StroblN, LangoschJM. Psychotropic drug-induced change of weight: a review. Fortschr Neurol Psychiatr, 75: 65–80, 2007.
5.
Education Medicaid Integrity Contract for the CMS Medicaid Integrity Program: Atypical Antipsychotic Medications: Use in Pediatric Patients. 2013http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-pediatric-factsheet.pdf. [Accessed 23July2015]
6.
KrentzAJ, BaileyCJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 65: 385–411, 2005.
7.
WuRR, ZhaoJP, JinH, ShaoP, FangMS, GuoXF, HeYQ, LiuYJ, ChenJD, LiLH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA, 299: 185–193, 2008.